As Praluent Q1 sales miss Wall Street expectations, FDA expands drug's label to reflect CV risk reduction
Months after sparring rivals Amgen $AMGN and partners Regeneron $REGN and Sanofi $SNY slashed the prices of their respective PCSK9 inhibitors by 60% to $5,850 in a bid to improve tepid sales of the cholesterol drugs, the latter has secured an additional label that supports their product’s ability to reduce serious cardiovascular events.
Regeneron/Sanofi’s Praluent and Amgen’s Repatha were originally approved in 2015 amidst much fanfare, and were pegged to attain blockbuster status for their ability to dramatically lower levels of LDL cholesterol, but instead faced pushback from insurers for their high sticker prices ($14,000) that led to lower-than-expected adoption, despite later trials that demonstrated the PCSK9 inhibitors also significantly cut the risk of heart attacks and strokes.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters